David Weill, Director at TransMedics Group, Inc. (TMDX), bought 1,336 shares at $81.63 ($109K) on 2026-09-11, disclosed to the SEC on 2026-09-14.
Open-market purchase of $109k TMDX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| TMDX | SELL | 2025-05-23 | $181K | — | Filing → |
| TMDX | SELL | 2024-05-31 | $338K | — | Filing → |
| TMDX | SELL | 2024-05-14 | $325K | — | Filing → |